To include your compound in the COVID-19 Resource Center, submit it here.

Actelion cardiovascular, metabolic news

Actelion shareholders backed the current board's strategy by rejecting all proposals from activist shareholder Elliott Advisors at the biotech's annual meeting on May 5. Chairman

Read the full 258 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE